Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194323 · ClinicalTrials.gov registry record
Biology in Patients With Reflux Esophagitis
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 75
- Enrollment target
NCT01194323 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants.
The verdict
NCT01194323 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
GERD is a common condition in the western world. In most cases, the diagnostic is established by good response to empiric proton pump inhibitor (PPI) therapy. When the patient symptoms are refractory to therapy, multiple invasive tests are available. The results of those tests (EGD, manometry, Ph monitoring and impedance) are clues that the physician use together to establish the diagnostic. No test however can be use alone because of their poor specificity and sensitivity. Recently, microscopy has been used to detect dilated intercellular space in between distal esophageal cells tissue; unfortunately this marker again failed to diagnose GERD. In search of more sensitive and specific markers of GERD, we propose to assess if acid exposure affects: 1) gene and proteins expression in the esophageal/post-cricoid area tissue; and 2) local impedance of the mucosa. The secondary aim of this proposal is to determine if correlation exists between the two approaches.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194323
The ClinicalTrials.gov registry entry for NCT01194323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01194323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194323 about?
NCT01194323 is a clinical study titled "Biology in Patients With Reflux Esophagitis". GERD is a common condition in the western world. In most cases, the diagnostic is established by good response to empiric proton pump inhibitor (PPI) therapy. When the patient symptoms are refractory to therapy, multiple invasive tests are available. The results of those tests (EGD, manometry, Ph mo...
What is the current status of trial NCT01194323?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2010-11. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT01194323?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.